公开(公告)号：US20240150427A1

公开(公告)日：2024-05-09

申请号：US18507469

申请日：2023-11-13

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Tong Zhang ,  Charles L. Sentman

IPC: C07K14/705 ,  A61K35/17 ,  A61K38/10 ,  A61K45/06 ,  C07K14/715

CPC classification number: C07K14/705 ,  A61K35/17 ,  A61K38/10 ,  A61K45/06 ,  C07K14/715

Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

公开(公告)号：US20220402996A1

公开(公告)日：2022-12-22

申请号：US17841117

申请日：2022-06-15

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Tong Zhang ,  Charles L. Sentman

IPC: C07K14/705 ,  A61K35/17 ,  C07K14/715 ,  A61K45/06 ,  A61K38/10

Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

公开(公告)号：US20220348627A1

公开(公告)日：2022-11-03

申请号：US17748683

申请日：2022-05-19

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Tong Zhang ,  Charles L. Sentman

IPC: C07K14/705 ,  A61K38/10 ,  C07K14/715 ,  A61K35/17 ,  A61K45/06

Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

公开(公告)号：US11034766B2

公开(公告)日：2021-06-15

申请号：US15784342

申请日：2017-10-16

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman ,  Tong Zhang

IPC: C07K16/28 ,  C07K14/705 ,  A61K39/395 ,  C07K14/725

Abstract: Antibodies, chimeric antigen receptors, and bispecific T-cell engagers having specificity for B7-H6 and methods for using the same in the diagnosis and treatment of disorders associated with B7-H6 expression are provided.

公开(公告)号：US20180320134A1

公开(公告)日：2018-11-08

申请号：US15966103

申请日：2018-04-30

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K39/00 ,  A61K35/17 ,  A61K35/12

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US09822340B1

公开(公告)日：2017-11-21

申请号：US15383662

申请日：2016-12-19

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/10 ,  C12N5/0783 ,  A61K35/17 ,  A61K35/12

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5156 ,  A61K2039/585 ,  C12N2501/515 ,  C12N2510/02 ,  C12N2511/00

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US20150152181A1

公开(公告)日：2015-06-04

申请号：US14399835

申请日：2013-05-07

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman ,  Tong Zhang

IPC: C07K16/28 ,  C07K14/725 ,  A61K39/395 ,  C07K14/705

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/33

Abstract: Antibodies, chimeric antigen receptors, and bispecific T-cell engagers having specificity for B7-H6 and methods for using the same in the diagnosis and treatment of disorders associated with B7-H6 expression are provided.

Abstract translation: 提供了具有B7-H6特异性的抗体，嵌合抗原受体和双特异性T细胞诱导剂及其在诊断和治疗与B7-H6表达相关的病症中的应用。

公开(公告)号：US11834676B2

公开(公告)日：2023-12-05

申请号：US17844982

申请日：2022-06-21

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  A61K35/12

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5156 ,  A61K2039/585 ,  C12N2501/515 ,  C12N2510/02 ,  C12N2511/00

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US10689618B2

公开(公告)日：2020-06-23

申请号：US15948303

申请日：2018-04-09

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K35/17 ,  A61K39/00 ,  A61K35/12

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

公开(公告)号：US10689616B1

公开(公告)日：2020-06-23

申请号：US15815197

申请日：2017-11-16

Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Charles L. Sentman

IPC: C12N5/0783 ,  A61K39/00 ,  A61K35/17 ,  A61K35/12

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.